03.05.2016 - Ipsen is strengthening its ties to long-time development partner Oncodesign, a Dijon-based cancer treatment biotech. The French pharma is handing over the pre-clinical pharmacology for its oncology research programmes to Oncodesign.
The two companies have worked together on R&D projects for the past 20 years, before sealing a drug discovery partnership in 2012. Now, Ipsen and Oncodesign have entered into a strategic oncology partnership, which has Oncodesign handling the pre-clinical pharmacology for Ipsen’s research projects in oncology.
Ipsen will use experimental models and new pharmacological approaches based on Oncodesign’s pharmaco-imaging and the detection of biomarkers. In return, Oncodesign will receive a minimum guaranteed annual fee to cover the cost of its research efforts in addition to potential variable payments, linked to business volumes generated by Ipsen’s programmes.
The strategic collaboration of the companies also covers the relocation of some of Oncodesign’s teams to Ipsen’s R&D centre in Paris-Saclay. “This new partnership represents a shift from a collaborative model that has already proven its value to a more extensive collaboration over a renewable five-year term through the creation of a joint research team based both at Ipsen’s Les Ulis facility and Oncodesign’s facility in Dijon,” the companies said in a statement.
“This partnership with Oncodesign fits perfectly with the development of Ipsen’s new R&D model, in which our Paris-Saclay platform will become a private open innovation campus,” added Christophe Thurieau, Ipsen Innovation’s Senior Vice-President, Worldwide Scientific Affairs.
29.04.2016 Swiss bank Group UBS has raised US$471m (€412m) for the UBS Oncology Impact Fund, which was set up to invest in early-stage cancer treatments. The money raised by the fund, nearly half of which comes from investors in Asia, is the largest amount ever raised for such a cancer investment fund.
27.04.2016 More revenue, more jobs, more financing, more R&D expenditure – all signs point towards sustainable growth in the German biotech sector. These are the results of the most recent company survey 2016, published by biotechnologie.de. The report was once again conducted alongside the biotech standards defined by the organisation for economic cooperation and development (OECD).
21.04.2016 An expert panel’s final report on the fatal drug trial earlier this year in France states that the death of one of the participants was most likely caused by the drug’s toxicity and not by any violation of the rules.
21.04.2016 For up to US$685m (€606m), Dutch ArgenX has outlicensed its human antibody programme ARGX-115 to AbbVie. The pre-clinical immuno-oncology candidate targets a protein believed to contribute to immunosuppressive effects of T-cells.
19.04.2016 British drug developer Heptares Therapeutics and mAb maker Kymab Ltd have partnered up in yet another immuno-oncology collaboration. The companies plan to discover antibody meds targeting a superfamily of receptors.
15.04.2016 Not every company is put off by the current stock market climate. Swiss biopharma company GeNeuro has gone public at Euronext Paris, raising €33m in the process. Others, meanwhile, have to find different ways to raise money.
13.04.2016 Despite political disturbances, 2015 was a good year for the biotech scene in Switzerland. Net sales increased by 5.1% to CHF5,133m and 400 additional people found jobs in the sector. As usual, the new numbers were presented at the annual Swiss Biotech Day – which set new records as well.
12.04.2016 German-Dutch life science investment specialist Forbion Capital Partners has raised more than €180m for its venture capital fund Forbion Capital Fund III. Once more the money will primarily go to European start-ups.